Reuters logo
BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial
September 11, 2017 / 5:46 AM / 13 days ago

BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial

Sept 10 (Reuters) - IPSEN SA:

* ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

* CABOZANTINIB PROVIDED STATISTICALLY SIGNIFICANT IMPROVEMENT OF PROGRESSION-FREE SURVIVAL, WITH A 52 PERCENT REDUCTION IN THE RATE OF PROGRESSION OR DEATH COMPARED TO SUNITINIB

Source text: bit.ly/2jhhRFC Further company coverage:, (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below